{{medical}}
{{drugbox
| verifiedrevid = 388076813
| IUPAC_name = (6''R'',7''R'')-7-{[(2''E'')-2-(2-amino-1,3-thiazol-4-yl)-<br>2-methoxyimino-acetyl]amino}-3-[(1-methyltetrazol-<br>5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]<br>oct-2-ene-2-carboxylic acid
| image = Cefmenoxime.svg
| ChemSpiderID = 7845223
| UNII_Ref = {{fdacite}}
| UNII = KBZ4844CXN
| InChI = 1/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)CSc4nnnn4C)C(=O)O
| InChIKey = HJJDBAOLQAWBMH-YCRCPZNHBH
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 65085-01-0
| ATC_prefix = J01
| ATC_suffix = DD05
| ATC_supplemental = 
| PubChem = 9570757
| DrugBank = APRD00851
| C = 16 | H = 17 | N = 9 | O = 5 | S = 3
| molecular_weight = 511.562 g/mol
| bioavailability = 100%（[[肌肉注射|肌肉注射]]） 
| protein_bound = 50% to 70%
| metabolism = 可忽略
| elimination_half-life = 1小时
| excretion = [[肾|肾]]，不变
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = 
| routes_of_administration = 口服、[[肌肉注射|肌肉注射]]、[[静脉注射|静脉注射]]
}}
'''头孢甲肟'''也称为“'''头孢噻肟四唑'''”“'''头孢氨噻肟唑'''”“'''噻肟唑头孢'''”“'''氨噻肟唑头孢菌素'''”“'''倍司特克'''”或“'''CMX'''”，是一种[[头孢菌素#第三代|第三代头孢菌素]]，属于为半合成[[抗生素|抗生素]]。头孢甲肟抗菌谱与其它第三代头孢菌素类似，对[[革兰氏阴性菌|革兰氏阴性菌]]有较高疗效，且对各种阴性菌产生的[[β内酰胺酶|β内酰胺酶]]特别稳定，具有杀菌作用。

==相互作用==
*[[呋塞米|呋塞米]]、{{link-en|依他尼酸|Etacrynic acid}}、{{link-en|布美他尼|Bumetanide}}等强[[利尿药|利尿药]]，{{link-en|卡氮芥|Carmustine}}、[[链佐星|链佐星]]等[[抗肿瘤药|抗肿瘤药]]及[[氨基糖苷类抗生素|氨基糖苷类抗生素]]等[[肾毒性药物|肾毒性药物]]与本品合用有增加肾毒性的可能。
*{{link-en|克拉维酸|Clavulanic acid}}可增强头孢甲肟对某些因产生[[β内酰胺酶|β内酰胺酶]]而对此抗生素具有[[耐药性|耐药性]]的革兰阴性杆菌的抗菌活性。
*口服{{link-en|丙磺舒|Probenecid}}会延迟头孢甲肟的代谢。

==外部链接==
* {{DiseasesDB|30892}}
* {{cite journal | author = Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T | title = Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis | journal = Jpn J Antibiot | volume = 48 | issue = 5 | pages = 602–9 | year = 1995 | pmid = 7637194}}
* {{cite journal | author = Paladino J, Fell R | title = Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia | journal = Ann Pharmacother | volume = 28 | issue = 3 | pages = 384–9 | year = 1994 | pmid = 8193431}}
* {{cite journal | author = Duncker G, Reich U, Krausse R | title = Cefmenoxime in corneal organ culture | journal = Ophthalmologica | volume = 208 | issue = 5 | pages = 262–6 | year = 1994 | pmid = 7816419 | doi = 10.1159/000310505}}

{{CephalosporinAntiBiotics}}

[[Category:头孢菌素|Category:头孢菌素]]
[[Category:噻唑|Category:噻唑]]
[[Category:四唑|Category:四唑]]
[[Category:肟|Category:肟]]